Oncolytics To Study REOLYSIN In Combination With GM-CSF In Pediatric Patients

(RTTNews) - Oncolytics Biotech Inc. (ONC.TO, ONCY) announced that following submission to the U.S. FDA for review, the Investigational New Drug Application containing the protocol titled "MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors" is now active.

The study is an open-label Phase I trial to clarify the safety, and determine possible efficacy, of GM-CSF given prior to administration of intravenous REOLYSIN for children with malignant high grade brain tumors. GM-CSF will be administered on days one and two of each cycle with REOLYSIN administered on days three, four and five.